sellModerate cluster of 3
MPM BioVentures 2014, L.P. sold $5.1M of ITOS
other at iTeos Therapeutics, Inc.. 630,191 shares at an average of $8.06, traded May 13, 2025, filed May 15, 2025.
Warning score
53Value
$5.1M
630,191 shares
Holdings after
2,108,594
-23% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +8RoleOther
- +25Trade size$5.1M at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-013248, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 13, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -630,191 | $8.06 | $5.1M | 2,108,594 | May 15, 2025 |
Related signals
Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.0M 104,565 shares | -72% | |
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.6M 156,847 shares | -109% | |
| 33Weak | iTeos Therapeutics, Inc. | David Hallal director | $1.2M 114,682 shares | -300% | |
| 42Moderate | ITOSbuy iTeos Therapeutics, Inc. | EcoR1 Capital, LLC owner | $39M 4,958,978 shares | +87% | |
| 53Moderate | iTeos Therapeutics, Inc. | Ansbert Gadicke other | $8.3M 1,031,931 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Mpm Bioventures 2018, L.p. other | $5.1M 630,191 shares | -23% | |
| 31Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $39k 5,000 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.